AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 224997 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 288
Study 6660827 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline solution, 10 ml per 1000 g of patient weight injected into the peritoneal cavity before closing the incision.
Number of subjects: 173
Study 6660827 — intervention group
Group type: COMPARATOR
Intervention: Control group (no saline solution injection).
Number of subjects: 173
Study 31564256 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushing technique
Number of subjects: 43
Study 31564256 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral laminectomy
Number of subjects: 43
Study 29398576 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tVNS treatment
Number of subjects: 41
Study 29398576 — intervention group
Group type: COMPARATOR
Intervention: Sham tVNS treatment
Number of subjects: 41
Study 26614422 — intervention group
Group type: EXPERIMENTAL
Intervention: G1: 5' at 9±1°C
Number of subjects: 100
Study 26614422 — intervention group
Group type: EXPERIMENTAL
Intervention: G2: 5' at 14±1°C
Number of subjects: 100
Study 26614422 — intervention group
Group type: EXPERIMENTAL
Intervention: G3: 15' at 9±1°C
Number of subjects: 100
Study 26614422 — intervention group
Group type: EXPERIMENTAL
Intervention: G4: 15' at 14±1°C
Number of subjects: 100
Study 26614422 — intervention group
Group type: COMPARATOR
Intervention: CG: control group
Number of subjects: 100
Study 25152605 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID-muscovite group (3 g of muscovite + 75 mg slow-release diclofenac, twice daily for 14 d)
Number of subjects: 30
Study 25152605 — intervention group
Group type: COMPARATOR
Intervention: NSAID control group (75 mg slow-release diclofenac, twice daily for 14 d)
Number of subjects: 30
Study 22985580 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum total P1NP
Number of subjects: 136
Study 22985580 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum β‐CTX
Number of subjects: 136
Study 22985580 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D3
Number of subjects: 136
Study 22985580 — intervention group
Group type: COMPARATOR
Intervention: Bone mineral density (BMD)
Number of subjects: 136
Study 22985580 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum total P1NP and β‐CTX
Number of subjects: 136
Study 20016013 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate ([(58)Fe]ferrous sulfate)
Number of subjects: 36
Study 20016013 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous fumarate ([(57)Fe]ferrous fumarate)
Number of subjects: 36
Study 20016013 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrected fractional iron absorption in children
Number of subjects: 36
Study 18817237 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg
Number of subjects: 70
Study 18817237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 15630172 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal lactoferrin, 319 mg per day for four weeks
Number of subjects: 15
Study 15630172 — intervention group
Group type: COMPARATOR
Intervention: Non-liposomal lactoferrin
Number of subjects: 15
Study 11789395 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril + indapamide treatment
Number of subjects: 0
Study 11789395 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril alone
Number of subjects: 0
Study 11789395 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment specified)
Number of subjects: 0
Study 9435041 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin (1.5 g/day)
Number of subjects: 287
Study 9435041 — intervention group
Group type: COMPARATOR
Intervention: Meropenem (3.0 g/day)
Number of subjects: 287
Study 8352687 — intervention group
Group type: EXPERIMENTAL
Intervention: Macular heterotopia
Number of subjects: 69
Study 8352687 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal fold
Number of subjects: 69
Study 2442551 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg (increased to 80 mg if necessary)
Number of subjects: 490
Study 2442551 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg (increased to 200 mg if necessary)
Number of subjects: 490
Study 2442551 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 12.5 or 25 mg added after 12 weeks if necessary
Number of subjects: 490
Study 28899914 — intervention group
Group type: EXPERIMENTAL
Intervention: Strenuous military training (4-day, 51-km cross-country ski march)
Number of subjects: 25
Study 28899914 — intervention group
Group type: EXPERIMENTAL
Intervention: Strenuous military training
Number of subjects: 25
Study 27769293 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (weekend group session at a spa resort, expert conferences, focus group activities, supervised by a psychotherapist)
Number of subjects: 12
Study 27769293 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Number of subjects: 12
Study 27769293 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 12
Study 24619576 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% lidocaine sprayed on the laryngoscope blade (group L)
Number of subjects: 72
Study 24619576 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% lidocaine sprayed on the trachea (group V)
Number of subjects: 72
Study 24619576 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% lidocaine sprayed on both the laryngoscope blade and trachea (group LV)
Number of subjects: 72
Study 24619576 — intervention group
Group type: COMPARATOR
Intervention: No lidocaine (group C)
Number of subjects: 72
Study 22039086 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine + Bevacizumab (CB)
Number of subjects: 99
Study 22039086 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine + Bevacizumab + Mitomycin C (CBM)
Number of subjects: 99
Study 22039086 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine (C)
Number of subjects: 99
Study 20618964 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicory root extract (600 mg/day, 1200 mg/day, 1800 mg/day for 1 month)
Number of subjects: 40
Study 20618964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17519819 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive follow-up (CT scan, fibreoptic bronchoscopy)
Number of subjects: 0
Study 17519819 — intervention group
Group type: COMPARATOR
Intervention: Simple follow-up (clinical examination, chest x-ray)
Number of subjects: 0
Study 16259626 — intervention group
Group type: EXPERIMENTAL
Intervention: Resource-oriented music therapy (biweekly sessions for three months)
Number of subjects: 144
Study 16259626 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 144
Study 11890453 — intervention group
Group type: COMPARATOR
Intervention: No-stent group
Number of subjects: 55
Study 11890453 — intervention group
Group type: COMPARATOR
Intervention: Stent group
Number of subjects: 55
Study 9532410 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2-based therapy (same as originally used)
Number of subjects: 159
Study 9532410 — intervention group
Group type: EXPERIMENTAL
Intervention: Different interleukin-2-based therapy (including tumor-infiltrating lymphocytes)
Number of subjects: 159
Study 9532410 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2 alone
Number of subjects: 159
Study 9532410 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical metastasectomy
Number of subjects: 159
Study 9532410 — intervention group
Group type: COMPARATOR
Intervention: Interleukin-2-based therapy (initial response)
Number of subjects: 159
Study 9532410 — intervention group
Group type: COMPARATOR
Intervention: Interleukin-2-based therapy (partial response)
Number of subjects: 159
Study 9532410 — intervention group
Group type: COMPARATOR
Intervention: Interleukin-2-based therapy (complete response)
Number of subjects: 159
Study 7989976 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐L,L‐EC
Number of subjects: 50
Study 7989976 — intervention group
Group type: COMPARATOR
Intervention: 99mTc‐MAG3
Number of subjects: 50
Study 7989976 — intervention group
Group type: COMPARATOR
Intervention: 125I‐OIH
Number of subjects: 50
Study 2455927 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate
Number of subjects: 7
Study 2455927 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 7
Study 2455927 — intervention group
Group type: COMPARATOR
Intervention: Placebo sodium cromoglycate
Number of subjects: 7
Study 2455927 — intervention group
Group type: COMPARATOR
Intervention: Placebo nifedipine
Number of subjects: 7
Study 31576915 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 80
Study 31576915 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 27628581 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (specific intervention not detailed)
Number of subjects: 449
Study 26321368 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO)
Number of subjects: 75
Study 26321368 — intervention group
Group type: COMPARATOR
Intervention: Air (placebo)
Number of subjects: 75
Study 25125271 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered HIV/HCV risk assessment plus brief intervention about drug misuse and screening for HIV/HCV
Number of subjects: 395
Study 25125271 — intervention group
Group type: COMPARATOR
Intervention: Self-administered HIV/HCV risk assessment alone (control)
Number of subjects: 395
Study 25125271 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms offered free combined rapid HIV/HCV screening
Number of subjects: 395
Study 22842984 — intervention group
Group type: EXPERIMENTAL
Intervention: IORT (20 Gy)
Number of subjects: 305
Study 22842984 — intervention group
Group type: EXPERIMENTAL
Intervention: IORT + WBRT
Number of subjects: 305
Study 22842984 — intervention group
Group type: COMPARATOR
Intervention: WBRT (50-56 Gy)
Number of subjects: 305
Study 19690657 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathectomy at the T2 level
Number of subjects: 60
Study 19690657 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathectomy at the T3 level
Number of subjects: 60
Study 19690657 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 60
Study 17564103 — intervention group
Group type: EXPERIMENTAL
Intervention: Propiverine alone (monotherapy group, n = 52)
Number of subjects: 100
Study 17564103 — intervention group
Group type: EXPERIMENTAL
Intervention: Propiverine plus urapidil (combination group, n = 48)
Number of subjects: 100
Study 15637975 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated system (IntelliClean System from Sonicare and Crest)
Number of subjects: 100
Study 15637975 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush with conventional toothpaste
Number of subjects: 100
Study 11466989 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training programme (twice a week for three months)
Number of subjects: 25
Study 9465812 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative administration of two injections of leuprolide acetate 28 days apart (group A)
Number of subjects: 67
Study 9465812 — intervention group
Group type: COMPARATOR
Intervention: Direct surgery (group B)
Number of subjects: 67
Study 7486614 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS 1102 (aptiganel hydrochloride) administered in doses of up to 100 micrograms/kg
Number of subjects: 55
Study 7486614 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS 1102 administered as a 15-minute intravenous infusion, a 15-minute loading intravenous infusion followed by a 4-hour maintenance infusion, or as a fixed-dose intravenous bolus over 90 seconds
Number of subjects: 55
Study 7486614 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS 1102
Number of subjects: 55
Study 2650735 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 g margarine added to soup
Number of subjects: 6
Study 2650735 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 g margarine added to mashed potato
Number of subjects: 6
Study 964056 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment with neomycin and bacitracin for 4 days preoperatively
Number of subjects: 108
Study 964056 — intervention group
Group type: COMPARATOR
Intervention: Mechanical and dietary preparation only (Control)
Number of subjects: 108
Study 964056 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment with neomycin and bacitracin
Number of subjects: 108
Study 31059146 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (lower dose) in secondary adrenal insufficiency
Number of subjects: 39
Study 31059146 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (higher dose) in secondary adrenal insufficiency
Number of subjects: 39
Study 31059146 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable hydrocortisone and fludrocortisone therapy in primary adrenal insufficiency
Number of subjects: 39
Study 31059146 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary adrenal insufficiency
Number of subjects: 39
Study 31059146 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary adrenal insufficiency with higher endogenous cortisol production
Number of subjects: 39
Study 28596150 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (PGB) + Alpha-lipoic acid (ALA) combination
Number of subjects: 54
Study 28596150 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin (PGB)
Number of subjects: 54
Study 28596150 — intervention group
Group type: COMPARATOR
Intervention: Alpha-lipoic acid (ALA)
Number of subjects: 54
Study 24651301 — intervention group
Group type: EXPERIMENTAL
Intervention: AryoSeven (30 μg/kg, intravenously per week for 4 weeks)
Number of subjects: 0
Study 24651301 — intervention group
Group type: COMPARATOR
Intervention: NovoSeven (30 μg/kg, intravenously per week for 4 weeks)
Number of subjects: 0
Study 24651301 — intervention group
Group type: EXPERIMENTAL
Intervention: AryoSeven
Number of subjects: 0
Study 24651301 — intervention group
Group type: COMPARATOR
Intervention: NovoSeven
Number of subjects: 0
Study 22364530 — intervention group
Group type: EXPERIMENTAL
Intervention: Amine fluoride toothpaste and gel (Elmex(®))
Number of subjects: 26
Study 22364530 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% spray-chlorhexidine (Perio-Aid(®))
Number of subjects: 26
Study 22364530 — intervention group
Group type: COMPARATOR
Intervention: Brush teeth without toothpaste (Control group)
Number of subjects: 26
Study 22364530 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive status and requirement for assistance
Number of subjects: 26
Study 20880042 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate U.S.$25 cash
Number of subjects: 0
Study 20880042 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate U.S.$25 check
Number of subjects: 0
Study 20880042 — intervention group
Group type: EXPERIMENTAL
Intervention: Promised U.S.$25 check
Number of subjects: 0
Study 20880042 — intervention group
Group type: EXPERIMENTAL
Intervention: Promised U.S.$25 check requiring an SSN
Number of subjects: 0
Study 19667268 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with paclitaxel (AC followed by paclitaxel)
Number of subjects: 1942
Study 19667268 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy without paclitaxel (AC only)
Number of subjects: 1942
Study 19667268 — intervention group
Group type: EXPERIMENTAL
Intervention: High Tau protein expression
Number of subjects: 1942
Study 19667268 — intervention group
Group type: EXPERIMENTAL
Intervention: Tau expression
Number of subjects: 1942
Study 17328809 — intervention group
Group type: EXPERIMENTAL
Intervention: Back School Programme (n = 50)
Number of subjects: 102
Study 17328809 — intervention group
Group type: COMPARATOR
Intervention: Clinic group (n = 52)
Number of subjects: 102
Study 15025551 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled iloprost 2.5 or 5 microg six or nine times daily for 12 weeks
Number of subjects: 101
Study 11683189 — intervention group
Group type: EXPERIMENTAL
Intervention: CVC (percutaneous longlines)
Number of subjects: 49
Study 11683189 — intervention group
Group type: COMPARATOR
Intervention: Peripheral cannulae
Number of subjects: 49
Study 10806696 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 30 mg orally
Number of subjects: 14
Study 10806696 — intervention group
Group type: COMPARATOR
Intervention: Intravenous magnesium sulfate (control)
Number of subjects: 14
Study 1996187 — intervention group
Group type: COMPARATOR
Intervention: Slow release diltiazem (maximum dose 360 mg daily)
Number of subjects: 24
Study 1996187 — intervention group
Group type: COMPARATOR
Intervention: Slow release diltiazem (minimum dose 120 mg)
Number of subjects: 24
Study 1996187 — intervention group
Group type: COMPARATOR
Intervention: Slow release diltiazem (up to 360 mg daily)
Number of subjects: 24
Study 1996187 — intervention group
Group type: COMPARATOR
Intervention: Slow release diltiazem
Number of subjects: 24
Study 6434435 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate
Number of subjects: 0
Study 6434435 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone cyclohexanecarboxylate
Number of subjects: 0
Study 30371982 — intervention group
Group type: EXPERIMENTAL
Intervention: One-to-one low-intensity interventions (LIIs)
Number of subjects: 8
Study 29524476 — intervention group
Group type: EXPERIMENTAL
Intervention: MVP ON phase
Number of subjects: 70
Study 29524476 — intervention group
Group type: COMPARATOR
Intervention: MVP OFF phase
Number of subjects: 70
Study 29524476 — intervention group
Group type: EXPERIMENTAL
Intervention: MVP ON and OFF phases
Number of subjects: 70
Study 26768753 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided audio-visual relaxation intervention
Number of subjects: 28
Study 26768753 — intervention group
Group type: COMPARATOR
Intervention: Recorded sickle cell discussion (Control)
Number of subjects: 28
Study 23307827 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral treprostinil (0.25 mg tablets)
Number of subjects: 349
Study 23307827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 349
Study 21321676 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimmed nasal cannula (TNC)
Number of subjects: 836
Study 21321676 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal mask (NM)
Number of subjects: 836
Study 21321676 — intervention group
Group type: COMPARATOR
Intervention: Nasal cannula (NC)
Number of subjects: 836
Study 19525834 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid caudal epidural injections (CEI) containing 12 mL of xylocaine 2% and 1 mL of betamethasone dipropionate and betamethasone phosphate (2 + 5) mg/dL
Number of subjects: 183
Study 19525834 — intervention group
Group type: COMPARATOR
Intervention: Water for Injection (WFI) caudal epidural injections containing 12 mL of xylocaine 2% and 8 mL of WFI
Number of subjects: 183
Study 18181310 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic sodium chloride enema
Number of subjects: 300
Study 18181310 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic sodium phosphate enema
Number of subjects: 300
Study 15149416 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioversion
Number of subjects: 38
Study 11395819 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 11
Study 11395819 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy (OA)
Number of subjects: 11
Study 10382124 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy (omeprazole, 20 mg bid, and amoxicillin, 1 gm bid, or clarithromycin, 500 mg tid)
Number of subjects: 369
Study 10382124 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (omeprazole, 20 mg bid, plus metronidazole, 500 mg bid, and amoxicillin, 1,000 mg bid, or clarithromycin, 500 mg tid)
Number of subjects: 369
Study 10382124 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (omeprazole, 20 mg bid, plus metronidazole, 500 mg bid, plus tetracycline, 500 mg qid, or doxycycline, 100 mg tid)
Number of subjects: 369
Study 10155202 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmaz-Schatz stent
Number of subjects: 50
Study 10155202 — intervention group
Group type: COMPARATOR
Intervention: Strecker stent
Number of subjects: 50
Study 2789925 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ICS 205-930
Number of subjects: 12
Study 2789925 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg ICS 205-930
Number of subjects: 12
Study 2789925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2789925 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS 205-930
Number of subjects: 12
Study 795183 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflucortolone valerate fatty ointment
Number of subjects: 60
Study 795183 — intervention group
Group type: COMPARATOR
Intervention: Fluocinolone acetonide ointment
Number of subjects: 60
Study 30537098 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (400 mg/day for 7 days)
Number of subjects: 46
Study 30537098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 30537098 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 46
Study 30537098 — intervention group
Group type: COMPARATOR
Intervention: Progesterone and Placebo
Number of subjects: 46
Study 26419583 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei strain Shirota-fermented milk (LcS-FM)
Number of subjects: 96
Study 26419583 — intervention group
Group type: COMPARATOR
Intervention: Control milk (CM)
Number of subjects: 96
Study 26349284 — intervention group
Group type: EXPERIMENTAL
Intervention: RFA-1
Number of subjects: 40
Study 26349284 — intervention group
Group type: EXPERIMENTAL
Intervention: RFA-2
Number of subjects: 40
Study 23213077 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive facilitative exercise (RFE) - 100 standardized movements of at least 5 joints of the affected upper extremity, 40 min/day, 5 days/week for 4 weeks.
Number of subjects: 52
Study 23213077 — intervention group
Group type: COMPARATOR
Intervention: Conventional upper-extremity rehabilitation program; same duration and frequency as RFE.
Number of subjects: 52
Study 22433807 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of reamberin and cycloferon
Number of subjects: 160
Study 22433807 — intervention group
Group type: COMPARATOR
Intervention: Generally accepted therapy
Number of subjects: 160
Study 19447808 — intervention group
Group type: EXPERIMENTAL
Intervention: High RVP (RVP 94%, n = 24)
Number of subjects: 213